Beijing Tong Ren Tang Chinese Medicine Company Limited Receives Proprietary Chinese Medicine Registration Certificate in Macau

Key Points for Investors

• Regulatory Approval: Beijing Tong Ren Tang Chinese Medicine Company Limited (“the Company”) announced that its subsidiary, Beijing Tong Ren Tang (Macau) Company Limited (“TRT Macau”), has received the Certificate of Registration of Proprietary Chinese Medicine from the Pharmaceutical Administration Bureau of Macao Special Administrative Region Government.
• Product Registration: The registered medicine, Jin Chai Shi Hu San【Tong Ren Tang】 (金釵石斛散【同仁堂】), can now be legally sold in Macau.
• Investment in R&D: The Company has invested approximately HK\$2 million (unaudited) in developing this proprietary Chinese medicine.
• Potential Market Expansion: The approval allows the product to enter the Macau market, which could lead to new revenue streams and business growth.
• Risk Factors: The Board notes that the registration will not have any material impact on the Company’s production, operation, or performance for the time being. Sales in Macau may be affected by changes in policy, exchange rate fluctuations, and market competition.

Detailed Analysis

Beijing Tong Ren Tang Chinese Medicine Company Limited, a Hong Kong-incorporated company listed on the Stock Exchange of Hong Kong (Stock Code: 3613), has voluntarily announced a significant development regarding its business activities in Macau.

TRT Macau, the Company’s subsidiary, has secured approval from the Pharmaceutical Administration Bureau of the Macau SAR Government to sell its proprietary medicine, Jin Chai Shi Hu San【Tong Ren Tang】 (金釵石斛散【同仁堂】), in Macau. The registration number for this product is MAC-C00315.

Product Information: Jin Chai Shi Hu San is indicated for a variety of health conditions, including:

• Heat disease consuming fluid
• Dry mouth, vexation, and thirst
• Stomach yin deficiency
• Reduced food intake and retching
• Deficiency heat after illness recovery
• Yin deficiency with effulgent fire
• Steaming bone and consumptive fever
• Dim and blurred vision
• Limp, witting sinew, and bone

This broad range of indications positions the medicine as a potential solution for multiple chronic and post-illness conditions prevalent within the population.

The Company’s cumulative investment of approximately HK\$2 million (unaudited) in research and development for Jin Chai Shi Hu San demonstrates its commitment to innovation and market expansion. This investment, while modest relative to the Company’s overall scale, could pave the way for future product launches in Macau and other regions.

Implications for Shareholders

• Share Price Sensitivity: The approval of Jin Chai Shi Hu San for sale in Macau introduces a new revenue opportunity for the Company. While the initial impact may be limited, investors should monitor future sales performance and market reception in Macau, as positive outcomes could affect the Company’s earnings and valuation.
• Market Risks: The Company cautions that, at present, the registration will not materially affect its production, operation, or financial performance. Sales may be influenced by regulatory changes, currency fluctuations, and competition. Shareholders should exercise caution and be aware of these risks.
• Strategic Expansion: This development signals the Company’s ongoing efforts to expand its footprint outside mainland China, potentially positioning it for greater international presence if the model proves successful in Macau.

Board and Governance

The Board is led by Chairman Yan Han, with a mix of executive, non-executive, and independent non-executive directors, ensuring robust corporate governance and oversight.

Conclusion

The registration of Jin Chai Shi Hu San in Macau is a noteworthy milestone for Beijing Tong Ren Tang Chinese Medicine Company Limited, marking its entry into the Macau proprietary Chinese medicine market. While immediate financial impact is expected to be minimal, this development could lay the groundwork for future growth and market expansion. Investors should monitor subsequent sales data and regulatory developments to assess potential share price movement.

Disclaimer

This article is provided for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The Company’s future performance may be influenced by regulatory, economic, and market factors beyond those described herein.

View TONGRENTANGCM Historical chart here